Dr. Reddy's Laboratories Limited Q3 2025 Financial Results

Dr. Reddy's Laboratories Limited reported its unaudited condensed consolidated interim financial statements for the quarter ended September 30, 2025. The company achieved a profit of $319 million, with revenues of $1.954 billion. The financial statements were prepared in accordance with International Accounting Standard 34 (IAS 34) and include convenience translations into U.S. dollars. The company's main segments include Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment contributed the majority of the revenue, amounting to $1.541 billion. The company also highlighted forward-looking statements, emphasizing potential risks and uncertainties that could impact future performance.